Best peptides for sleep quality
Peptides that improve sleep onset, depth, and overall sleep architecture through growth hormone and neurological pathways.
What to know
GH secretagogues taken before bed enhance deep sleep through natural GH pulsing. Ipamorelin is the most popular for sleep improvement — minimal side effects and clean GH release. DSIP (Delta Sleep-Inducing Peptide) directly targets sleep architecture but has limited research. MK-677 improves sleep but may cause next-morning grogginess and appetite increase. Timing matters: take GH peptides 30-60 minutes before bed on an empty stomach.
Recommended peptides
Ipamorelin
gh-secretagogue
Ipamorelin is a synthetic pentapeptide and growth hormone releasing peptide (GHRP) that stimulates the pituitary gland to secrete growth hormone through selective activation of the ghrelin receptor (GHS-R1a). Developed in the late 1990s by Novo Nordisk, it was characterized in a landmark 1999 study as the first GHRP to release GH with absolute selectivity, meaning it does not significantly elevate cortisol, prolactin, ACTH, FSH, or LH at pharmacological doses (PMID: 10580762). This hormonal selectivity distinguishes it from older GHRPs like GHRP-2 and GHRP-6, which produce meaningful cortisol and prolactin elevations that can complicate long-term use. Ipamorelin is most commonly combined with CJC-1295 (a GHRH analog) to produce synergistic GH release through dual-pathway stimulation. The two peptides act on different receptors and when administered together produce GH output substantially greater than either compound alone. This combination has become one of the most widely used peptide protocols in anti-aging medicine and performance-oriented use. Ipamorelin was placed on the FDA Category 2 bulk drug substance list in 2023, restricting compounding pharmacy production, though regulatory status remained in flux following a February 2026 announcement from HHS regarding potential reinstatement of certain peptides.
CJC-1295
gh-secretagogue
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) engineered to dramatically extend the half-life of natural GHRH signaling. Developed by ConjuChem Biotechnologies in the early 2000s, it exists in two distinct forms that are frequently confused: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC, also known as Modified GRF (1-29) or mod GRF 1-29. Understanding this distinction is essential — they share a name but have fundamentally different pharmacokinetic profiles. The DAC version uses a reactive chemical group called maleimidopropionic acid (MPA) that forms a covalent bond with serum albumin after injection. This albumin binding shields the peptide from enzymatic degradation and extends its half-life from minutes to 5.8-8.1 days (PMID: 16352683). Native GHRH has a half-life of approximately 7 minutes, making this roughly a 1,000-fold improvement in duration. The landmark Teichman et al. trial demonstrated that a single CJC-1295 DAC injection produced dose-dependent GH increases of 2- to 10-fold sustained for 6 or more days, with IGF-I levels rising 1.5- to 3-fold for 9-11 days (PMID: 16352683). The no-DAC version (mod GRF 1-29) has four amino acid substitutions at positions 2, 8, 15, and 27 that improve stability against dipeptidylpeptidase-IV (DPP-IV) cleavage compared to native GHRH, but without albumin binding, its half-life is approximately 30 minutes. This shorter duration preserves the natural pulsatile pattern of GH release — the body's own rhythm of GH spikes followed by quiet periods — which many researchers and clinicians consider preferable to the continuous elevation produced by the DAC form. A critical finding from the Ionescu and Frohman study confirmed that even the DAC version preserves GH pulsatility: basal GH levels increased 7.5-fold, but GH pulse frequency and magnitude remained unchanged, meaning the pituitary's natural secretory rhythm was maintained rather than overridden (PMID: 17018654). This is a meaningful safety distinction from exogenous HGH, which produces flat, supraphysiologic GH levels that suppress the body's own production. CJC-1295 has never been FDA-approved for any indication. A Phase II clinical trial of the DAC version for HIV-associated lipodystrophy was halted in July 2006 after a participant died hours after his 11th injection at an Argentine study site. The cause of death was confirmed as acute myocardial infarction. The attending physician attributed the MI to pre-existing asymptomatic coronary artery disease unrelated to CJC-1295 treatment. The study enrolled 192 HIV-positive participants with significant cardiovascular risk factors, and ConjuChem eventually went bankrupt without completing the trial. The FDA flagged cardiac concerns when reviewing CJC-1295 during the 2024 PCAC process, indicating the regulatory signal was not fully dismissed. This remains the only reported fatality associated with CJC-1295. CJC-1295 was placed on the FDA Category 2 bulk drug substance list in late 2023, effectively prohibiting compounding pharmacies from preparing it. In September 2024, the FDA referred it to the Pharmacy Compounding Advisory Committee (PCAC), which flagged cardiac side effects and immunogenicity concerns. On February 27, 2026, HHS Secretary RFK Jr. announced that approximately 14 of 19 restricted peptides would return to legal compounding status, though the specific list has not been officially published and CJC-1295's inclusion remains uncertain due to its cardiac flagging. CJC-1295 is prohibited at all times by WADA under S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics.
DSIP
other
DSIP (Delta Sleep Inducing Peptide) is a neuropeptide that promotes delta wave sleep, the deepest and most restorative phase of the sleep cycle.
BPC-157
healing-recovery
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids derived from a protective protein found naturally in human gastric juice. First isolated and characterized by researcher Predrag Sikiric and his team at the University of Zagreb in the early 1990s, BPC-157 has become one of the most extensively studied peptides in preclinical research, with over 100 published studies investigating its effects across multiple organ systems. The compound earned the nickname "the Wolverine peptide" in biohacking communities due to the breadth of tissue repair observed in animal studies. Research spanning more than three decades has documented effects on tendons, ligaments, muscles, bones, skin, corneas, the gastrointestinal tract, liver, and nervous system in preclinical models. A 2025 systematic review published in HSS Journal (PMID: 40756949) analyzed 36 studies conducted between 1993 and 2024, finding that BPC-157 consistently improved outcomes across musculoskeletal injury models. Despite this extensive preclinical evidence, human clinical data remains extremely limited. As of March 2026, only three small human studies have been published: a 2-person intravenous safety pilot (PMID: 40131143), a small retrospective knee pain study, and a 12-patient interstitial cystitis pilot. The knee pain study reported significant relief in most participants at 6-12 months, and the cystitis pilot reported substantial symptom improvement. Neither of these smaller studies has been published with full peer-reviewed PMIDs. A Phase I safety trial (NCT02637284) was registered by PharmaCotherapia but the sponsor never published results, raising transparency concerns in the research community. BPC-157 is classified as a research compound and is not FDA-approved for any human use. In 2023, the FDA placed BPC-157 in Category 2 of its list of bulk drug substances under evaluation for compounding, meaning it does not meet safety criteria for pharmacy compounding. The World Anti-Doping Agency (WADA) added BPC-157 to its prohibited substances list in 2022 under the S0 category (non-approved substances). Despite these regulatory designations, BPC-157 continues to be widely discussed in peptide research communities and functional medicine circles. The compound is available in injectable and oral forms. Most preclinical research has used subcutaneous or intraperitoneal injection, though studies have also demonstrated activity when administered orally, particularly for gastrointestinal conditions. An important distinction exists between the acetate salt and arginate salt forms. The arginate form reportedly demonstrates significantly better oral bioavailability and stability, though head-to-head bioavailability studies have not been published in peer-reviewed journals. A comprehensive preclinical safety evaluation published in Regulatory Toxicology and Pharmacology (PMID: 32334036) tested BPC-157 across multiple species including mice, rats, rabbits, and dogs. The study found no test-related adverse effects in single-dose or repeated-dose toxicity evaluations, no genetic toxicity, and no embryo-fetal toxicity at doses up to 20 mg/kg over six weeks. However, the absence of large-scale human safety trials means that the long-term safety profile in humans remains unknown. The primary mechanisms through which BPC-157 appears to exert its effects involve the promotion of angiogenesis, modulation of nitric oxide synthesis through multiple pathways, upregulation of growth factor receptors, and interaction with the dopamine and serotonin neurotransmitter systems. These mechanisms have been documented across dozens of studies spanning multiple research groups. BPC-157 occupies a unique position in the peptide landscape. Its broad preclinical evidence base across tissue types, combined with the near-total absence of human clinical trials, creates a significant gap between what animal research suggests and what has been demonstrated in people. All information on this page reflects published research and is presented for educational purposes only.
Get the Sleep Quality cheat sheet
Dosing quick-reference, key studies, and side effect management — in your inbox.
Recommended stacks
GH Optimization Stack
intermediate — $100-250
Growth hormone secretagogue stack combining GHRP and GHRH for synergistic GH release without exogenous HGH.
Sleep & Recovery Stack
beginner — $60-120
Optimize deep sleep and overnight recovery using GH peptides timed to amplify the natural nighttime growth hormone surge.
The GH Optimization Stack
intermediate — $100-250
The most popular growth hormone secretagogue combination. CJC-1295 (a GHRH analog) and ipamorelin (a GHRP) work through complementary receptor pathways to produce synergistic GH release without the side effects of exogenous HGH.
The Recovery Stack
intermediate — $120-250
Combines the two most popular healing peptides with DSIP (Delta Sleep-Inducing Peptide) to optimize both tissue repair and sleep quality. Healing happens primarily during deep sleep, making this combination uniquely synergistic.
The Sleep & Recovery Stack
beginner — $80-170
Targets both sleep architecture and overnight recovery through three complementary pathways. DSIP enhances delta wave sleep, pinealon supports natural melatonin production, and BPC-157 accelerates tissue repair during the amplified deep sleep window.
Explore other goals
Get the Peptide Starter Kit (free)
Quick-start guide to GLP-1 peptides, dosing basics, and what to ask your doctor.
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated June 2026